Meyers & Flowers warning Diabetics about serious genital infections linked to SGLT2 Inhibitors, a class of popular Diabetes drugs
Meyers & Flowers is advising those with Type II Diabetes about a recent U.S. Food and Drug Administration (FDA) warning. The agency has received several reports of Fournier’s Gangrene or necrotizing fasciitis cases linked to popular sodium-glucose cotransporter-2 (SGLT2) Inhibitors including Invokana, Jardiance, Farxiga, and Streglatro.
Fournier’s gangrene is a rare, but life-threatening, bacterial infection that affects the tissue, muscles, nerves, and blood vessels of the perineum and surrounding genital area. While this type of necrotizing fasciitis, also known as flesh-eating bacteria, not only causes the genital tissue to die it can also stretch to the thighs, stomach, and chest.
Typically, the bacteria enter the body through a cut and spreads quickly. Over the past three years, the FDA has identified 12 cases of Fournier’s gangrene, to date seven men and five women have contracted the genital infection. All patients had to be hospitalized for surgical procedures. Several required multiple surgeries, leading to serious disfigurement. One patient died due to the infection.
SGLT2 inhibitors were first approved in 2013 and are prescribed to lower blood sugar in adults with type 2 diabetes. FDA-approved SGLT2 inhibitors include Johnson & Johnson’s Invokana, Eli Lilly & Co’s Jardiance, and medications from Bristol-Myers Squibb, Astra Zeneca Plc, Merck & Co and Pfizer Inc.
This new warning adds to previous warnings from the FDA. In the past, the government agency stated canagliflozin, a sodium-glucose cotransporter-2 (SGLT2) drug, may cause an increased the risk of developing ketoacidosis, an increased risk of risk of foot and leg amputations as well as acute kidney injury.
If you or a loved one has developed Fournier’s gangrene after taking an SGLT2 inhibitor such as Invokana, Jardiance, Farxiga, or Streglatro, contact Meyers & Flowers to research your legal options. We can be reached at email@example.com or at 877-221-2511.